NEW YORK (
) hit a new 52-week low Monday as it is currently trading at $2.26, below its previous 52-week low of $2.27 with 1.5 million shares traded as of 2:56 p.m. ET. Average volume has been 1.7 million shares over the past 30 days.
Savient has a market cap of $168 million and is part of the
industry. Shares are down 79.4% year to date as of the close of trading on Friday.
Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Savient as a
. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and generally weak debt management. You can view the full
or get investment ideas from our